IVA vs LLY vs MRK vs AZN

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -47. 4% for Inventiva S. A. (IVA). Merck & Co. , Inc. (MRK) offers the better valuation at 16. 4x trailing P/E (23. 2x forward), making it the more compelling value choice. Analysts rate Inventiva S. A. (IVA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 16. 4x versus Eli Lilly and Company at 49. 4x. On forward P/E, AstraZeneca PLC is actually cheaper at 17. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: AstraZeneca PLC wins at 0. 80x versus Merck & Co. , Inc. 's 1. 09x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.

1%, compared to -75. 2% for Inventiva S. A. (IVA). Over 10 years, the gap is even starker: LLY returned +1485% versus IVA's -71. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 32β versus Inventiva S. A. 's 1. 59β — meaning IVA is approximately 394% more volatile than MRK relative to the S&P 500. On balance sheet safety, AstraZeneca PLC (AZN) carries a lower debt/equity ratio of 61% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -47. 4% for Inventiva S. A. (IVA). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to -45. 7% for Inventiva S. A.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -20. 0% for Inventiva S. A. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -1060. 6% for IVA. At the gross margin level — before operating expenses — IVA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, AstraZeneca PLC (AZN) is the more undervalued stock at a PEG of 0. 80x versus Merck & Co. , Inc. 's 1. 09x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, AstraZeneca PLC (AZN) trades at 17. 4x forward P/E versus 30. 9x for Eli Lilly and Company — 13. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IVA: 328. 6% to $16. 50.

In this comparison, MRK (2.

7% yield), AZN (1. 8% yield), LLY (0. 5% yield) pay a dividend. IVA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1485% 10Y return). Inventiva S. A. (IVA) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1485%, IVA: -71. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IVA is a small-cap quality compounder stock; LLY is a mega-cap high-growth stock; MRK is a large-cap deep-value stock; AZN is a large-cap quality compounder stock. LLY, MRK, AZN pay a dividend while IVA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.